Loading clinical trials...
Loading clinical trials...
A Phase 2b Study to Evaluate the Efficacy and Safety of Mavrilimumab in Subjects With Moderate-to-Severe Rheumatoid Arthritis
Conditions
Interventions
Mavrilimumab 30 mg
Mavrilimumab 100 mg
+2 more
Locations
42
Argentina
Research Site
Ciudad Autonoma de Buenos Aire, Argentina
Research Site
Rosario, Argentina
Research Site
San Miguel de Tucumán, Argentina
Research Site
Plovdiv, Bulgaria
Research Site
Sofia, Bulgaria
Research Site
Santiago, Chile
Start Date
August 1, 2012
Primary Completion Date
December 1, 2013
Completion Date
January 1, 2014
Last Updated
September 27, 2016
NCT07484243
NCT06647069
NCT06841562
NCT07268326
NCT07233655
NCT07029555
Lead Sponsor
MedImmune LLC
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions